Furthermore, we combined all possible pairs of two of these three biomarkers (i.e., CD45neg EpCAMpos CTC count (≥3/7 mL as a cutoff), CD45neg EpCAMneg cell count (≥500/7 mL as a cutoff), and CEA level (>5 ng/mL as a cutoff)) to distinguish CRC stages and statuses. This evidence concerns the gene CEACAM5 and colorectal carcinoma.